Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 162.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 163.50
  • 52 Week Low: 101.00
  • Currency: UK Pounds
  • Shares Issued: 106.69m
  • Volume: 171,545
  • Market Cap: £173.37m
  • RiskGrade: 456

Cello Health injects pharma duo to board of directors

By Duncan Ferris

Date: Thursday 16 Aug 2018

LONDON (ShareCast) - (Sharecast News) - Healthcare advisory group Cello Health on Thursday appointed independent non-executive directors Clifford Tompsett and Jo LeCouilliard to its board of directors.
The move follows Paul Hamilton and Will David standing down as non-executive directors with immediate effect after both having served as members of the AIM traded company's board for more than a decade.

Mark Scott, chief executive of Cello, said: "I am delighted that the group has secured the services of two, highly experienced and capable new non-executive directors with deep experience across the pharmaceutical industry. The board very much looks forward to working with Clifford and Jo as we shape the future growth path for the group."

Tompsett was most recently a senior partner at PriceWaterhouseCoopers, where he held responsibility over the firm's global cross border IPO practice and led its UK and European activities in the pharmaceutical sector, and will head the audit committee and serve as senior independent director.

Meanwhile, LeCouilliard, who is currently a non-executive director of Circassia Pharmaceuticals, has held a number of senior positions in Asia and the US at GlaxoSmithKline, as well as at BMI Healthcare.

Cello's shares were up 0.77% at 131.50p at 1646 BST.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 162.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 163.50
52 Week Low 101.00
Volume 171,545
Shares Issued 106.69m
Market Cap £173.37m
RiskGrade 456

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
85.92% below the market average85.92% below the market average85.92% below the market average85.92% below the market average85.92% below the market average
13.51% below the sector average13.51% below the sector average13.51% below the sector average13.51% below the sector average13.51% below the sector average
Price Trend
86.30% above the market average86.30% above the market average86.30% above the market average86.30% above the market average86.30% above the market average
40.00% above the sector average40.00% above the sector average40.00% above the sector average40.00% above the sector average40.00% above the sector average
Income
76.88% below the market average76.88% below the market average76.88% below the market average76.88% below the market average76.88% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Growth
30.87% below the market average30.87% below the market average30.87% below the market average30.87% below the market average30.87% below the market average
35.29% below the sector average35.29% below the sector average35.29% below the sector average35.29% below the sector average35.29% below the sector average

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 1
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  2nd Interim Interim
Ex-Div 23-Apr-20 03-Oct-19
Paid 22-May-20 01-Nov-19
Amount 1.00p 1.15p

Trades for 16-Jul-2020

Time Volume / Share Price
16:28 8,187 @ 162.00p
16:28 2,320 @ 162.00p
16:05 5,867 @ 162.00p
16:00 125,500 @ 162.16p
15:52 125,000 @ 162.00p

Cello Health Key Personnel

CEO Mark Scott

Top of Page